Healthcare Services
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Valuation | |
|---|---|
| Market Cap | 69.53 kCr |
| Price/Earnings (Trailing) | 72.41 |
| Price/Sales (Trailing) | 7.87 |
| EV/EBITDA | 36.48 |
| Price/Free Cashflow | 143.04 |
| MarketCap/EBT | 55.03 |
| Enterprise Value | 72.63 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 8.84 kCr |
| Rev. Growth (Yr) | 16.6% |
| Earnings (TTM) | 981.02 Cr |
| Earnings Growth (Yr) | -22.4% |
Profitability | |
|---|---|
| Operating Margin | 15% |
| EBT Margin | 14% |
| Return on Equity | 10.12% |
| Return on Assets | 6.53% |
| Free Cashflow Yield | 0.70% |
Growth & Returns | |
|---|---|
| Price Change 1W | 0.50% |
| Price Change 1M | 9.1% |
| Price Change 6M | -1.4% |
| Price Change 1Y | 51% |
| 3Y Cumulative Return | 48.8% |
| 5Y Cumulative Return | 42.1% |
| 7Y Cumulative Return | 31.5% |
| 10Y Cumulative Return | 18.4% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -779.38 Cr |
| Cash Flow from Operations (TTM) | 1.42 kCr |
| Cash Flow from Financing (TTM) | -713.84 Cr |
| Cash & Equivalents | 101.17 Cr |
| Free Cash Flow (TTM) | 576.99 Cr |
| Free Cash Flow/Share (TTM) | 7.64 |
Balance Sheet | |
|---|---|
| Total Assets | 15.01 kCr |
| Total Liabilities | 5.32 kCr |
| Shareholder Equity | 9.69 kCr |
| Current Assets | 2.54 kCr |
| Current Liabilities | 1.72 kCr |
| Net PPE | 6.6 kCr |
| Inventory | 127.34 Cr |
| Goodwill | 4.53 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.21 |
| Debt/Equity | 0.33 |
| Interest Coverage | 3.24 |
| Interest/Cashflow Ops | 7.51 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1 |
| Dividend Yield | 0.11% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Past Returns: Outperforming stock! In past three years, the stock has provided 48.8% return compared to 12.8% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 45.2% growth over past three years, the company is going strong.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
No major cons observed.
Past Returns: Outperforming stock! In past three years, the stock has provided 48.8% return compared to 12.8% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 45.2% growth over past three years, the company is going strong.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.11% |
| Dividend/Share (TTM) | 1 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 12.72 |
Financial Health | |
|---|---|
| Current Ratio | 1.47 |
| Debt/Equity | 0.33 |
Technical Indicators | |
|---|---|
| RSI (14d) | 76.39 |
| RSI (5d) | 55.29 |
| RSI (21d) | 68.44 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 5, 2025
The stock has returned -3.48% in the last day, reflecting recent market volatility.
Fortis Malar Hospitals has seen a decline of -6.36% over the past month.
Current trading showed volatility with a low of ₹74.76, indicating market uncertainty.
Summary of Fortis Healthcare's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
During the Q3 FY '26 earnings call, management of Fortis Healthcare provided a positive outlook for the company, indicating sustained growth in both the hospital and diagnostics segments. For Q3 FY '26, consolidated revenues reached INR 2,265 crores, a 17.5% increase year-on-year. Hospital revenues increased by 19.4% to INR 1,938 crores, while diagnostic revenues grew by 7.3% to INR 327 crores. The operating EBITDA for the quarter rose by 34.8% to INR 505 crores, yielding a margin of 22.3%, up from 19.4% in Q3 FY '25.
Looking at the nine-month performance, consolidated revenues were INR 6,763 crores, reflecting a growth of 17.1%. Notably, the operating EBITDA margin improved by 300 basis points to 23%. Management reported a net debt of INR 2,547 crores, with a net debt-to-EBITDA ratio of 1.24x as of December 31, 2025.
Forward-looking initiatives include the successful acquisition of the 125-bedded People Tree Hospital in Bengaluru for INR 430 crores, which will enable expansion to over 300 beds. Management also highlighted the opening of a new specialized mental health care facility, Adayu, in Gurugram. An additional 750 operational beds were added this year. Furthermore, they foresee targeting around 400 new beds in FY '27, primarily through brownfield expansions at existing facilities.
In terms of doctor hiring for expanded capacities, management expressed confidence in attracting talent due to Fortis' strong brand presence. They predict stable ARPOB growth of about 4-5% annually and emphasized an ongoing focus on maintaining margins through strategic expansions and operational efficiencies. Overall, management remains optimistic about achieving a 20% top-line growth in FY '27 while also improving margins by an additional 150 basis points.
Understand Fortis Healthcare ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| NORTHERN TK VENTURE PTE. LTD. | 31.17% |
| HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | 5.96% |
| KOTAK AGGRESSIVE HYBRID FUND | 4.99% |
| AXIS ELSS TAX SAVER FUND | 3.12% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA | 2.37% |
| DSP ARBITRAGE FUND | 1.39% |
| FIDELITY FUNDS - INDIA FOCUS FUND |
Detailed comparison of Fortis Healthcare against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprises | 1.09 LCr | 24.42 kCr | +11.60% | +19.20% | 60.76 | 4.48 | - | - |
| MAXHEALTH | Max Healthcare Institute |
Comprehensive comparison against sector averages
FORTIS metrics compared to Healthcare
| Category | FORTIS | Healthcare |
|---|---|---|
| PE | 72.41 | 62.08 |
| PS | 7.87 | 6.31 |
| Growth | 16 % | 16.9 % |
Fortis Healthcare is a prominent hospital company headquartered in Gurugram, India, recognized by the stock ticker FORTIS. The company boasts a substantial market capitalization of Rs. 50,974.8 Crores and has established itself as an integrated healthcare delivery service provider.
Offering a wide range of specialized services, Fortis Healthcare provides secondary, tertiary, and quaternary care across various medical fields. These include, but are not limited to:
The company's healthcare verticals also encompass hospitals, diagnostics, and day care specialty facilities.
Founded in 1995, Fortis Healthcare has shown remarkable financial growth, achieving a trailing 12-month revenue of Rs. 7,618.4 Crores and recording a profit of Rs. 824.5 Crores over the past four quarters. The company has experienced an impressive 35.5% revenue growth in the last three years.
In terms of shareholder returns, Fortis Healthcare offers a dividend yield of 0.15% per year, distributing Rs.1 dividend per share in the last 12 months, demonstrating its commitment to providing value to its investors.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
FORTIS vs Healthcare (2021 - 2026)
Fortis Malar Hospitals has seen a significant gain of 29.63% over the last three months.
Earnings Call Transcript • 20 Feb 2026 The relevant disclosure is attached. |
General • 19 Feb 2026 The relevant disclosure is attached. |
Newspaper Publication • 17 Feb 2026 The relevant disclosure is attached. |
General • 16 Feb 2026 The relevant disclosure is attached. |
Analyst / Investor Meet • 16 Feb 2026 The relevant disclosure is attached. |
Newspaper Publication • 14 Feb 2026 The relevant disclosure is attached. |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Here are the major questions asked during the Q&A session of the Fortis Healthcare Limited earnings transcript, along with detailed responses:
Question: "How should we think about the People Tree acquisition in Bangalore, considering it's running sub-optimally? Will it require additional investment?" Answer: "We see the facility requiring some investment to meet Fortis standards. The first phase will be manageable in cost. We will also start expansion work to increase capacity to 300 beds. Thus, we expect this facility to evolve into a high-end, fully equipped super-specialty hospital over the next 3 to 4 years."
Question: "What would the organic bed addition next year be, excluding acquisitions?" Answer: "Next year, we are targeting around 400-plus beds in brownfield expansion. This includes enhancements primarily driven by the FMRI expansion, which we aim to commission by April."
Question: "What's the revenue contribution from Gleneagles for this quarter?" Answer: "We earned INR5 crores as O&M fee this quarter. Excluding Bombay, Gleneagles generated revenue of INR172 crores with an EBITDA of approximately 3% after absorbing our fees."
Question: "Have you started seeing impacts from higher CGHS and ECHS rates?" Answer: "Yes, we are beginning to see positive results from CGHS. However, ECHS still poses some uncertainties due to drug pricing issues. We anticipate benefits as clarity improves."
Question: "Can you provide details on your international patient revenue and its scalability?" Answer: "International patient revenue has stabilized at 8-9% of total revenue. We are focusing on markets in the West, East Africa, and the Middle East to enhance this segment, but geopolitical factors do affect the growth sustainably."
Question: "What's the expected guidance for FY '27 considering your thoughts on continuing growth?" Answer: "We're on a growth trajectory; while I cannot provide specific numbers, we expect a continued upward trend in revenue and margins. The brownfield expansions we discussed will bolster our performance."
Question: "What are your expectations regarding ARPOB growth in the coming years?" Answer: "We anticipate a 4-5% increase in ARPOB annually, driven by a mix of pricing powers and case complexity, particularly in oncology services."
Question: "Could you clarify your approach towards brownfield and greenfield expansions in the future?" Answer: "We plan an aggressive brownfield approach to strengthen existing clusters, along with some greenfield projects. This includes ongoing expansions in Jalandhar and potential additions in Greater Noida."
Question: "How do you see the competitive landscape amidst new entrants?" Answer: "Our competitive edge lies in our infrastructure, brand legacy, and physician engagement. Our commitment to clinical excellence continues to attract talent and retain our market position."
Question: "Regarding the potential equity raise by IHH, what should we expect in terms of timing and amount?" Answer: "The cooling period for additional equity will conclude in May, and we expect clarity on the amount and structure of potential investments thereafter. We are focused on balancing our balance sheet for future expansions."
| 1.35% |
| JUPITER INDIA FUND | 1.26% |
| AXIS BANK LIMITED | 1.19% |
| KOTAK FUNDS - INDIA MIDCAP FUND | 1.17% |
| EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- | 1.11% |
Distribution across major stakeholders
Distribution across major institutional holders
| 1.06 LCr |
| 8.3 kCr |
| +8.30% |
| +5.40% |
| 74.51 |
| 12.75 |
| - |
| - |
| NH | Narayana Hrudayalaya | 37.34 kCr | 6.88 kCr | +0.70% | +30.10% | 47.64 | 5.43 | - | - |
| ASTERDM | Aster DM Healthcare | 32.68 kCr | 4.58 kCr | +11.00% | +51.20% | 98.41 | 7.13 | - | - |
| MEDANTA | Global Health | 30.37 kCr | 4.27 kCr | +7.80% | -6.30% | 59.1 | 7.12 | - | - |
| KIMS | Krishna Institute of Medical Sciences | 27.53 kCr | 3.65 kCr | +12.80% | +26.90% | 91.73 | 7.55 | - | - |
| HCG | HealthCare Global Enterprises | 8.3 kCr | 2.5 kCr | -6.30% | +16.00% | 436 | 3.32 | - | - |
| -22.7% |
| 308 |
| 398 |
| 335 |
| 285 |
| 254 |
| 317 |
| Exceptional items before tax | -304% | -45.91 | 24 | 13 | -53.57 | 24 | -59.77 |
| Total profit before tax | -38% | 262 | 422 | 348 | 232 | 277 | 257 |
| Current tax | 14.9% | 55 | 48 | 40 | 34 | 45 | 52 |
| Deferred tax | -75% | 13 | 49 | 44 | 14 | -19.56 | 16 |
| Total tax | -30.2% | 68 | 97 | 84 | 49 | 25 | 68 |
| Total profit (loss) for period | -40.2% | 197 | 329 | 267 | 188 | 254 | 193 |
| Other comp. income net of taxes | -33.8% | 4.48 | 6.26 | -0.45 | -3.04 | 0.45 | -0.6 |
| Total Comprehensive Income | -39.8% | 202 | 335 | 266 | 185 | 255 | 192 |
| Earnings Per Share, Basic | -51.8% | 2.57 | 4.26 | 3.45 | 2.44 | 3.28 | 2.34 |
| Earnings Per Share, Diluted | -51.8% | 2.57 | 4.26 | 3.45 | 2.44 | 3.28 | 2.34 |
| Debt equity ratio | 0% | 035 | 033 | 028 | 027 | 0 | - |
| Debt service coverage ratio | 0.1% | 0.0177 | 0.0168 | 0.0592 | 0.0849 | 0.03 | - |
| Interest service coverage ratio | -1.9% | 0.0604 | 0.0778 | 0.0732 | 0.0681 | 0.09 | - |
| 10.2% |
| 207 |
| 188 |
| 175 |
| 154 |
| 148 |
| 155 |
| Finance costs | 37% | 112 | 82 | 106 | 130 | 141 | 160 |
| Depreciation and Amortization | 12% | 113 | 101 | 116 | 113 | 111 | 97 |
| Other expenses | 23.1% | 603 | 490 | 479 | 389 | 307 | 331 |
| Total Expenses | 20.8% | 1,415 | 1,172 | 1,142 | 989 | 857 | 891 |
| Profit Before exceptional items and Tax | 50.7% | 230 | 153 | 61 | 7.29 | -32.33 | 749 |
| Exceptional items before tax | -224.9% | -115.14 | 94 | 48 | -16.28 | 56 | -128.63 |
| Total profit before tax | -54.1% | 114 | 247 | 109 | -8.99 | 24 | 621 |
| Current tax | 7.4% | 30 | 28 | 8.78 | 2.3 | 13 | 112 |
| Deferred tax | 5.6% | 20 | 19 | 3.86 | 1.96 | 7.22 | -4.73 |
| Total tax | 8.7% | 51 | 47 | 13 | 4.26 | 20 | 107 |
| Total profit (loss) for period | -68.2% | 64 | 199 | 96 | -13.25 | 4.2 | 513 |
| Other comp. income net of taxes | -84.2% | -1.45 | -0.33 | -1.27 | 0.28 | 0.86 | -0.12 |
| Total Comprehensive Income | -69.2% | 62 | 199 | 95 | -12.97 | 5.06 | 513 |
| Earnings Per Share, Basic | -109.8% | 0.84 | 2.64 | 1.27 | -0.18 | 0.06 | 6.8 |
| Earnings Per Share, Diluted | -109.8% | 0.84 | 2.64 | 1.27 | -0.18 | 0.06 | 6.8 |
| Debt equity ratio | - | 022 | - | - | - | - | - |
| Debt service coverage ratio | - | 0.0205 | - | - | - | - | - |
| Interest service coverage ratio | - | 0.0407 | - | - | - | - | - |
| 31.7% |
| 55 |
| 42 |
| 119 |
| 259 |
| 280 |
| 2.67 |
| Goodwill | 0% | 27 | 27 | 27 | 27 | 27 | 27 |
| Non-current investments | -0.7% | 10,110 | 10,178 | 8,754 | 8,834 | 8,773 | 8,848 |
| Loans, non-current | 6.2% | 18 | 17 | 18 | 16 | 162 | 146 |
| Total non-current financial assets | -0.7% | 10,129 | 10,196 | 8,773 | 8,851 | 8,937 | 8,995 |
| Total non-current assets | -0.2% | 11,489 | 11,516 | 9,594 | 9,620 | 9,837 | 9,549 |
| Total assets | -0.1% | 11,985 | 11,999 | 10,388 | 10,387 | 10,335 | 10,369 |
| Borrowings, non-current | -0.8% | 1,885 | 1,901 | 401 | 514 | 580 | 625 |
| Total non-current financial liabilities | -0.8% | 1,885 | 1,901 | 401 | 514 | 580 | 627 |
| Provisions, non-current | 25% | 36 | 29 | 29 | 26 | 25 | 22 |
| Total non-current liabilities | -0.4% | 1,922 | 1,930 | 430 | 540 | 605 | 648 |
| Borrowings, current | 4.4% | 144 | 138 | 181 | 145 | 153 | 160 |
| Total current financial liabilities | -10.4% | 840 | 937 | 842 | 713 | 695 | 602 |
| Provisions, current | -4.2% | 24 | 25 | 22 | 22 | 22 | 22 |
| Current tax liabilities | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | -10.8% | 888 | 995 | 881 | 760 | 734 | 645 |
| Total liabilities | -3.9% | 2,810 | 2,925 | 1,311 | 1,300 | 1,339 | 1,405 |
| Equity share capital | 0% | 755 | 755 | 755 | 755 | 755 | 755 |
| Total equity | 1.1% | 9,175 | 9,074 | 9,077 | 9,087 | 8,996 | 8,964 |
| Total equity and liabilities | -0.1% | 11,985 | 11,999 | 10,388 | 10,387 | 10,335 | 10,369 |
| - |
| -2.03 |
| 0 |
| 34 |
| 49 |
| - |
| - |
| Other inflows (outflows) of cash | - | 0 | 0 | 0 | 14 | - | - |
| Net Cashflows From Operating Activities | 38.2% | 334 | 242 | 198 | 76 | - | - |
| Cashflows used in obtaining control of subsidiaries | -102.1% | 0 | 48 | 0 | 0.02 | - | - |
| Proceeds from sales of PPE | -100.4% | 0.34 | 150 | 0.15 | 0.18 | - | - |
| Purchase of property, plant and equipment | 12.3% | 365 | 325 | 54 | 27 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | 11638.5% | 76 | 0.35 | 100 | 123 | - | - |
| Dividends received | 475% | 70 | 13 | 21 | 0 | - | - |
| Interest received | 31% | 284 | 217 | 91 | 141 | - | - |
| Other inflows (outflows) of cash | 197.9% | 99 | -99.06 | 46 | 1.11 | - | - |
| Net Cashflows From Investing Activities | -3758.6% | -1,572.21 | 44 | 205 | 238 | - | - |
| Proceeds from issuing debt | - | 1,550 | 0 | 0 | 0 | - | - |
| Proceeds from borrowings | -99.6% | 1.96 | 241 | 54 | 218 | - | - |
| Repayments of borrowings | -73.3% | 80 | 297 | 319 | 359 | - | - |
| Payments of lease liabilities | - | 48 | 0 | 24 | 49 | - | - |
| Dividends paid | 0% | 75 | 75 | 0 | 0 | - | - |
| Interest paid | -11.1% | 73 | 82 | 106 | 129 | - | - |
| Income taxes paid (refund) | -104.5% | 0 | 23 | 0 | 0 | - | - |
| Net Cashflows from Financing Activities | 573.2% | 1,276 | -268.42 | -395.44 | -319.82 | - | - |
| Net change in cash and cash eq. | 117.6% | 38 | 18 | 7.59 | -5.59 | - | - |
Press Release / Media Release • 13 Feb 2026 The relevant disclosure is attached. |
Analysis of Fortis Healthcare's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Healthcare | 83.9% | 1.9 kCr |
| Diagnostic | 16.1% | 370.9 Cr |
| Total | 2.3 kCr |